N-tert-butyl hydroxylamine, a mitochondrial antioxidant, protects human retinal pigment epithelial cells from iron overload: relevance to macular degeneration

Ludmila A Voloboueva, David W Killilea, Hani Atamna, Bruce N Ames, Ludmila A Voloboueva, David W Killilea, Hani Atamna, Bruce N Ames

Abstract

Age-related macular degeneration (AMD) is the leading cause of severe visual impairment in the elderly in developed countries. AMD patients have elevated levels of iron within the retinal pigment epithelia (RPE), which may lead to oxidative damage to mitochondria, disruption of retinal metabolism, and vision impairment or loss. As a possible model for iron-induced AMD, we investigated the effects of excess iron in cultured human fetal RPE cells on oxidant levels and mitochondrial cytochrome c oxidase (complex IV) function and tested for protection by N-tert-butyl hydroxylamine (NtBHA), a known mitochondrial antioxidant. RPE exposure to ferric ammonium citrate resulted in a time- and dose-dependent increase in intracellular iron, which increased oxidant production and decreased glutathione (GSH) levels and mitochondrial complex IV activity. NtBHA addition to iron-overloaded RPE cells led to a reduction of intracellular iron content, oxidative stress, and partial restoration of complex IV activity and GSH content. NtBHA might be useful in AMD due to its potential to reduce oxidative stress, mitochondrial damage, and age-related iron accumulation, which may damage normal RPE function and lead to loss of vision.

Figures

Figure 1
Figure 1
Time-dependent increase in the levels of total iron in RPE cells treated with 250 µM FAC. Changes in total iron levels were measured using ICP. FAC exposure for 1–4 days promoted a time-dependent increase in the levels of total iron in RPE cells. The data represent mean ± sd of 3 independent experiments (***P<0.001).
Figure 2
Figure 2
Iron overload induced dose- and time-dependent increase in the levels of oxidative stress in RPE. A) Effect of different concentrations of FAC (4 days’ treatment) on the levels of intracellular oxidants. Changes in oxidative stress were measured with the oxidant-sensitive dye H2DCF. The significant increase in oxidant levels was induced by the concentrations of FAC of 250 µM or greater. The data represent mean ± sd of 6 samples from 3 different experiments (***P<0.001 vs. control). B) Time-dependent increase in the levels of intracellular oxidants in RPE cells treated with 250 µM FAC. The data represent mean ± sd of 6 samples from 3 different experiments (**P<0.01, ***P<0.001 vs. control).
Figure 3
Figure 3
Effects of NtBHA posttreatment on iron homeostasis and oxidative stress levels in RPE cells. A) NtBHA posttreatment resulted in a decrease in levels of total iron in RPE cells treated with FAC (250 µM, 4 days) as determined by ICP. RPE cells were treated with NtBHA (250 µM, 16 h) after FAC exposure, and demonstrated a significant decrease in the levels of total iron compared with RPE cells treated with medium alone (0 µM NtBHA). The data represent mean ± sd of 3 independent experiments (**P<0.01, ***P<0.001). B) Effect of iron overload and NtBHA posttreatment on the levels of labile iron in RPE cells. Different treatments are indicated as follows: control = untreated RPE cells; NtBHA = RPE cells treated with 250 µM NtBHA; FAC, 4 days = RPE cells treated with 250 µM FAC for 4 days; FAC + 0 µM NtBHA = RPE cells treated with 250 µM FAC for 4 days and posttreated with NtBHA-free cell medium; FAC + 250 µM NtBHA = RPE cells treated with 250 µM FAC for 4 days and posttreated with 250 µM NtBHA. Changes in labile iron levels were measured with Fe-sensitive calcein dye. FAC treatment for 4 days promoted significant decrease in calcein fluorescence, indicating increased labile iron concentration. Treatment with 250 µM NtBHA of iron-loaded cells reduced the levels of intracellular labile iron compared with RPE cells treated with medium alone (0 µM NtBHA). The data represent mean ± sd of 7 samples from 4 independent experiments (***P<0.001). C) Effect of NtBHA posttreatment on the levels of intracellular oxidants in iron-treated RPE cells. RPE cells were treated overnight (16 h) with different concentrations of NtBHA after 4 days of FAC exposure. Changes in oxidant levels were measured with oxidant-sensitive dye H2DCF. Data are expressed as mean ± sd of 3 independent experiments. Each experiment was performed in duplicate (**P<0.01, ***P<0.001). D) Fluorescein diacetate dye was used as a control to check for potential changes in RPE dye loading. Different treatments promoted no significant changes in fluorescein signal indicating no difference in loading differently treated RPE cells with dyes.
Figure 4
Figure 4
Effect of iron overload and NtBHA treatment on GSH levels in RPE cells. Control = untreated RPE cells; NtBHA = RPE cells treated with 250 µM NtBHA for 16 h; FAC, 4 days = RPE cells treated with 250 µM FAC for 4 days; FAC + 0 µM NtBHA = RPE cells treated with 250 µM FAC for 4 days and posttreated with NtBHA-free cell medium for 16 h; FAC + 250 µM NtBHA = RPE cells treated with 250 µM FAC for 4 days and posttreated with 250 µM NtBHA for 16 h. NtBHA treatment caused a significant increase in GSH levels in both control and FAC-treated RPE cells. The data represent mean ± sd of 5 samples from 3 different experiments (*P<0.05, ***P<0.001).
Figure 5
Figure 5
Effect of iron overload and NtBHA treatment on ferritin and transferrin receptor (TfR) expression in RPE cells. A) Different treatments are indicated: Contr = control untreated RPE cells; NtBHA = RPE cells treated with 250 µM NtBHA for 16 h; FAC, 4 days = RPE cells treated with 250 µM FAC for 4 days; FAC + 0 µM NtBHA = RPE cells treated with 250 µM FAC for 4 days, then treated with NtBHA-free cell medium for 16 h; FAC = 250 µM NtBHA = RPE cells treated with 250 µM FAC for 4 days, then treated with 250 µM NtBHA for 16 h. B) Effect of NtBHA (250 µM, 16 h) treatment on ferritin levels in RPE cells from 3 different donors.
Figure 6
Figure 6
Effect of iron overload and NtBHA treatment on mitochondrial complex IV activity. Control = untreated RPE cells; NtBHA = RPE cells treated with 250 µM NtBHA; FAC, 4 days = RPE cells treated with 250 µM FAC for 4 days; FAC + 0 µM NtBHA = RPE cells treated with 250 µM FAC for 4 days, then treated with NtBHA-free cell medium; FAC + 250 µM NtBHA = RPE cells treated with 250 µM FAC for 4 days, then treated with 250 µM NtBHA. Changes in the enzyme activity were measured using kinetic colorimetric assay. FAC treatment for 4 days caused a significant decrease in complex IV activity. Treatment with 250 µM NtBHA of iron overloaded cells resulted in a significant increase of complex IV activity compared with RPE cells treated with medium alone (0 µM NtBHA). Iron-loaded RPE cells treated with 250 µM NtBHA demonstrated significantly higher levels of complex IV activity compared with RPE cells treated with medium alone (0 µM NtBHA). The data represent mean ± sd of 3 independent experiments (*P<0.05 vs. control, **P<0.01).

References

    1. Harvey PT. Common eye diseases of elderly people: identifying and treating causes of vision loss. Gerontology. 2003;49:1–11.
    1. Hahn P, Ying GS, Beard J, Dunaief JL. Iron levels in human retina: sex difference and increase with age. NeuroReport. 2006;17:1803–1806.
    1. Hahn P, Milam AH, Dunaief JL. Maculas affected by age-related macular degeneration contain increased chelatable iron in the retinal pigment epithelium and Bruch’s membrane. Arch. Ophthalmol. 2003;121:1099–1105.
    1. Walter PB, Knutson MD, Paler-Martinez A, Lee S, Xu Y, Viteri FE, Ames BN. Iron deficiency and iron excess damage mitochondria and mitochondrial DNA in rats. Proc. Natl. Acad. Sci. U. S. A. 2002;99:2264–2269.
    1. Meneghini R. Iron homeostasis, oxidative stress, and DNA damage. Free Radic. Biol. Med. 1997;23:783–792.
    1. Henle ES, Luo Y, Gassmann W, Linn S. Oxidative damage to DNA constituents by iron-mediated fenton reactions. The deoxyguanosine family. J. Biol. Chem. 1996;271:21177–21186.
    1. Eaton JW, Qian M. Molecular bases of cellular iron toxicity. Free Radic. Biol. Med. 2002;32:833–840.
    1. Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE, Hofman A, Jensen S, Wang JJ, de Jong PT. Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology. 2001;108:697–704.
    1. Seddon JM, Ajani UA, Sperduto RD, Hiller R, Blair N, Burton TC, Farber MD, Gragoudas ES, Haller J, Miller DT, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-control Study Group. JAMA. 1994;272:1413–1420.
    1. Samiec PS, Drews-Botsch C, Flagg EW, Kurtz JC, Sternberg P, Jr, Reed RL, Jones DP. Glutathione in human plasma: decline in association with aging, age-related macular degeneration, and diabetes. Free Radic. Biol. Med. 1998;24:699–704.
    1. Cruickshanks KJ, Klein R, Klein BE, Nondahl DM. Sunlight and the 5-year incidence of early age-related maculopathy: the beaver dam eye study. Arch. Ophthalmol. 2001;119:246–250.
    1. Green WR, McDonnell PJ, Yeo JH. Pathologic features of senile macular degeneration. Ophthalmology. 1985;92:615–627.
    1. Hamdi HK, Kenney C. Age-related macular degeneration: a new viewpoint. Front. Biosci. 2003;8:e305–e314.
    1. Marmor M, Wolfensberger T, editors. The Retinal Pigment Epithelium: Function and Disease. New York: Oxford Univ. Press; 1998.
    1. Wangsa-Wirawan ND, Linsenmeier RA. Retinal oxygen: fundamental and clinical aspects. Arch. Ophthalmol. 2003;121:547–557.
    1. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv. Ophthalmol. 2000 0;45:115–134.
    1. Kennedy CJ, Rakoczy PE, Constable IJ. Lipofuscin of the retinal pigment epithelium: a review. Eye. 1995;9:763–771.
    1. Miceli MV, Liles MR, Newsome DA. Evaluation of oxidative processes in human pigment epithelial cells associated with retinal outer segment phagocytosis. Exp. Cell Res. 1994;214:242–249.
    1. Snodderly DM. Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins. Am. J. Clin. Nutr. 1995;62:1448S–1461S.
    1. Fliesler SJ, Anderson RE. Chemistry and metabolism of lipids in the vertebrate retina. Prog. Lipid. Res. 1983;22:79–131.
    1. Gardner HW. Oxygen radical chemistry of polyunsaturated fatty acids. Free Radic. Biol. Med. 1989;7:65–86.
    1. Lakhanpal V, Schocket SS, Jiji R. Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmology. 1984;91:443–451.
    1. Doly M, Bonhomme B, Vennat JC. Experimental study of the retinal toxicity of hemoglobinic iron. Ophthalmic Res. 1986;18:21–27.
    1. Rapp LM, Wiegand RD, Anderson RE. Ferrous ion-mediated retinal degeneration: role of rod outer segment peroxidation. In: Clayton RM, Haywood J, Reading HW, Wright A, editors. Problem of Normal and Genetically Abnormal Retinas. New York: Academic; 1982. pp. 109–119.
    1. Wang ZJ, Lam KW, Lam TT, Tso MO. Iron-induced apoptosis in the photoreceptor cells of rats. Invest. Ophthalmol. Vis. Sci. 1998;39:631–633.
    1. Vergara O, Ogden T, Ryan S. Posterior penetrating injury in the rabbit eye: effect of blood and ferrous ions. Exp. Eye Res. 1989;49:1115–1126.
    1. Tawara A. Transformation and cytotoxicity of iron in siderosis bulbi. Invest. Ophthalmol. Vis. Sci. 1986;27:226–236.
    1. Huang XP, O’Brien PJ, Templeton DM. Mitochondrial involvement in genetically determined transition metal toxicity I. Iron toxicity. Chem. Biol. Interact. 2006;163:68–76.
    1. Atamna H, Walter PB, Ames BN. The role of heme and iron-sulfur clusters in mitochondrial biogenesis, maintenance, and decay with age. Arch. Biochem. Biophys. 2002;397:345–353.
    1. Liang FQ, Godley BF. Oxidative stress-induced mitochondrial DNA damage in human retinal pigment epithelial cells: a possible mechanism for RPE aging and age-related macular degeneration. Exp. Eye Res. 2003;76:397–403.
    1. Feher J, Kovacs I, Artico M, Cavallotti C, Papale A, Balacco Gabrieli C. Mitochondrial alterations of retinal pigment epithelium in age-related macular degeneration. Neurobiol. Aging. 2006;27:983–993.
    1. Hunt RC, Davis AA. Release of iron by human retinal pigment epithelial cells. J. Cell Physiol. 1992;152:102–110.
    1. Yefimova MG, Jeanny JC, Keller N, Sergeant C, Guillonneau X, Beaumont C, Courtois Y. Impaired retinal iron homeostasis associated with defective phagocytosis in Royal College of Surgeons rats. Invest. Ophthalmol. Vis. Sci. 2002;43:537–545.
    1. Miyajima H, Nishimura Y, Mizoguchi K, Sakamoto M, Shimizu T, Honda N. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology. 1987;37:761–767.
    1. Morita H, Ikeda S, Yamamoto K, Morita S, Yoshida K, Nomoto S, Kato M, Yanagisawa N. Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. Ann. Neurol. 1995;37:646–656.
    1. Dunaief JL, Richa C, Franks EP, Schultze RL, Aleman TS, Schenck JF, Zimmerman EA, Brooks DG. Macular degeneration in a patient with aceruloplasminemia, a disease associated with retinal iron overload. Ophthalmology. 2005;112:1062–1065.
    1. Atamna H, Paler-Martinez A, Ames BN. N-t-butyl hydroxylamine, a hydrolysis product of alpha-phenyl-N-t-butyl nitrone, is more potent in delaying senescence in human lung fibroblasts. J. Biol. Chem. 2000;275:6741–6748.
    1. Atamna H, Robinson C, Ingersoll R, Elliott H, Ames BN. N-t-Butyl hydroxylamine is an antioxidant that reverses age-related changes in mitochondria in vivo and in vitro. FASEB J. 2001;15:2196–2204.
    1. Killilea DW, Atamna H, Liao C, Ames BN. Iron accumulation during cellular senescence in human fibroblasts in vitro. Antioxid. Redox Signal. 2003;5:507–516.
    1. Lee JH, Kim IS, Park JW. The use of N-t-butyl hydroxylamine for radioprotection in cultured cells and mice. Carcinogenesis. 2004;25:1435–1442.
    1. Kim HJ, Shin SW, Oh CJ, Lee MH, Yang CH, Park JW. N-t-Butyl hydroxylamine regulates heat shock-induced apoptosis in U937 cells. Redox Rep. 2005;10:287–293.
    1. Maminishkis A, Chen S, Jalickee S, Banzon T, Shi G, Wang FE, Ehalt T, Hammer JA, Miller SS. Confluent monolayers of cultured human fetal retinal pigment epithelium exhibit morphology and physiology of native tissue. Invest. Ophthalmol. Vis. Sci. 2006;47:6312–3624.
    1. Voloboueva LA, Liu J, Suh JH, Ames BN, Miller SS. (R)-α-lipoic acid protects retinal pigment epithelial cells from oxidative damage. Invest. Ophthalmol. Vis. Sci. 2005;46:4302–4310.
    1. Hoepken HH, Korten T, Robinson SR, Dringen R. Iron accumulation, iron-mediated toxicity and altered levels of ferritin and transferrin receptor in cultured astrocytes during incubation with ferric ammonium citrate. J. Neurochem. 2004;88:1194–1202.
    1. Bishop GM, Robinson SR. Quantitative analysis of cell death and ferritin expression in response to cortical iron: implications for hypoxia-ischemia and stroke. Brain Res. 2001;907:175–187.
    1. Brubacher JL, Bols NC. Chemically de-acetylated 2′,7′-dichlorodihydrofluorescein diacetate as a probe of respiratory burst activity in mononuclear phagocytes. J. Immunol. Methods. 2001;251:81–91.
    1. Epsztejn S, Kakhlon O, Glickstein H, Breuer W, Cabantchik I. Fluorescence analysis of the labile iron pool of mammalian cells. Anal. Biochem. 1997;248:31–40.
    1. Fariss MW, Reed DJ. High-performance liquid chromatography of thiols and disulfides: dinitrophenol derivatives. Methods Enzymol. 1987;143:101–109.
    1. Davis KJA. Oxidative Damage and Repair: Chemical, Biological and Medical Aspects. Oxford/New York: Pergamon Press; 1991.
    1. Gutteridge JM, Halliwell B. Iron toxicity and oxygen radicals. Baillieres Clin. Haematol. 1989;2:195–256.
    1. Yefimova MG, Jeanny JC, Guillonneau X, Keller N, Nguyen-Legros J, Sergeant C, Guillou F, Courtois Y. Iron, ferritin, transferrin, and transferrin receptor in the adult rat retina. Invest. Ophthalmol. Vis. Sci. 2000;41:2343–2351.
    1. Anderson DH, Talaga KC, Rivest AJ, Barron E, Hageman GS, Johnson LV. Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp. Eye Res. 2004;78:243–256.
    1. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer’s disease senile plaques. J. Neurol. Sci. 1998;158:47–52.
    1. Roca-Santiago HM, Lago-Bouza JR, Millan-Calenti JC, Gomez-Ulla-Irazazabal F. Alzheimer’s disease and age-related macular degeneration. Arch. Soc. Esp. Oftalmol. 2006;81:73–78.
    1. Atamna H, Boyle K. Amyloid-beta peptide binds with heme to form a peroxidase: relationship to the cytopathologies of Alzheimer’s disease. Proc. Natl. Acad. Sci. U. S. A. 2006;103:3381–3386.
    1. Paradies G, Ruggiero FM, Petrosillo G, Gadaleta MN, Quagliariello E. Effect of aging and acetyl-L-carnitine on the activity of cytochrome oxidase and adenine nucleotide translocase in rat heart mitochondria. FEBS Lett. 1994;350:213–215.
    1. Chen J, Schenker S, Frosto TA, Henderson GI. Inhibition of cytochrome c oxidase activity by 4-hydroxynonenal (HNE). Role of HNE adduct formation with the enzyme subunits. Biochim. Biophys. Acta. 1998;1380:336–344.
    1. Yu J, Wu L, Xu L. Detection and analysis of mitochondrial DNA mutation and oxidative phosphorylation in age-related macular degeneration patients. J. Fourth Military Med. Univ. 2003;24:805–808.
    1. Maurer I, Zierz S, Moller HJ. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol. Aging. 2000;21:455–462.
    1. Dhanasekaran A, Kotamraju S, Kalivendi SV, Matsunaga T, Shang T, Keszler A, Joseph J, Kalyanaraman B. Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis. J. Biol. Chem. 2004;279:37575–37587.
    1. Hahn P, Dentchev T, Qian Y, Rouault T, Harris ZL, Dunaief JL. Immunolocalization and regulation of iron handling proteins ferritin and ferroportin in the retina. Mol. Vis. 2004;10:598–607.
    1. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, Paw BH, Drejer A, Barut B, Zapata A, et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature. 2000;403:776–781.
    1. McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, Miret S, Bomford A, Peters TJ, Farzaneh F, et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol. Cell. 2000;5:299–309.
    1. Hahn P, Qian Y, Dentchev T, Chen L, Beard J, Harris ZL, Dunaief JL. Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and retinal degeneration with features of age-related macular degeneration. Proc. Natl. Acad. Sci. U. S. A. 2004;101:13850–13855.
    1. De Domenico I, Vaughn MB, Li L, Bagley D, Musci G, Ward DM, Kaplan J. Ferroportin-mediated mobilization of ferritin iron precedes ferritin degradation by the proteasome. EMBO J. 2006;25:5396–5404.
    1. Dunn LL, Rahmanto YS, Richardson DR. Iron uptake and metabolism in the new millennium. Trends. Cell Biol. 2007;17:93–100.
    1. Kwak MK, Wakabayashi N, Itoh K, Motohashi H, Yamamoto M, Kensler TW. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J. Biol. Chem. 2003;278:8135–8145.
    1. Suh JH, Shenvi SV, Dixon BM, Liu H, Jaiswal AK, Liu RM, Hagen TM. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc. Natl. Acad. Sci. U. S. A. 2004;101:3381–3386.
    1. Watts RN, Hawkins C, Ponka P, Richardson DR. Nitrogen monoxide (NO)-mediated iron release from cells is linked to NO-induced glutathione efflux via multidrug resistance-associated protein 1. Proc. Natl. Acad. Sci. U. S. A. 2006;103:7670–7675.
    1. Chen H, Zheng C, Zhang Y, Chang YZ, Qian ZM, Shen X. Heat shock protein 27 downregulates the transferrin receptor 1-mediated iron uptake. Int. J. Biochem. Cell Biol. 2006;38:1402–1416.
    1. Wetli HA, Buckett PD, Wessling-Resnick M. Small-molecule screening identifies the selanazal drug ebselen as a potent inhibitor of DMT1-mediated iron uptake. Chem. Biol. 2006;13:965–972.

Source: PubMed

3
Abonnieren